A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Trial Profile

A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Crenolanib (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Sponsors AROG Pharmaceuticals
  • Most Recent Events

    • 26 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Aug 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Actual initiation date (Apr 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top